Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001

被引:115
作者
Shimizu, H
Thorley, B
Paladin, FJ
Brussen, KA
Stambos, V
Yuen, L
Utama, A
Tano, Y
Arita, M
Yoshida, H
Yoneyama, T
Benegas, A
Roesel, S
Pallansch, M
Kew, O
Miyamura, T
机构
[1] Natl Inst Infect Dis, Dept Virol 2, Tokyo, Japan
[2] Victorian Infect Dis Reference Lab, Melbourne, Vic 3051, Australia
[3] Natl Epidemiol Ctr, Dept Hlth, Manila, Philippines
[4] WHO, Reg Off Western Pacific, Manila, Philippines
[5] CDCP, Natl Ctr Infect Dis, Resp & Enter Viruses Branch, Div Viral & Rickettsial Dis, Atlanta, GA USA
关键词
D O I
10.1128/JVI.78.24.13512-13521.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In 2001, highly evolved type 1 circulating vaccine-derived poliovirus (cVDPV) was isolated from three acute flaccid paralysis patients and one contact from three separate communities in the Philippines. Complete genomic sequencing of these four cVDPV isolates revealed that the capsid region was derived from the Sabin 1 vaccine strain but most of the noncapsid region was derived from an unidentified enterovirus unrelated to the oral poliovirus vaccine (OPV) strains. The sequences of the cVDPV isolates were closely related to each other, and the isolates had a common recombination site. Most of the genetic and biological properties of the cVDPV isolates were indistinguishable from those of wild polioviruses. However, the most recently identified cVDPV isolate from a healthy contact retained the temperature sensitivity and partial attenuation phenotypes. The sequence relationships among the isolates and Sabin 1 suggested that cVDPV originated from an OPV dose given in 1998 to 1999 and that cVDPV circulated along a narrow chain of transmission. Type 1 cVDPV was last detected in the Philippines in September 2001, and population immunity to polio was raised by extensive OPV campaigns in late 2001 and early 2002.
引用
收藏
页码:13512 / 13521
页数:10
相关论文
共 67 条
[1]   Duration of poliovirus excretion and fts implications for acute flaccid paralysis surveillance: A review of the literature [J].
Alexander, JP ;
Gary, HE ;
Pallansch, MA .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 :S176-S182
[2]  
[Anonymous], 2001, Wkly Epidemiol Rec, V76, P319
[3]   Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient [J].
Bellmunt, A ;
May, G ;
Zell, R ;
Pring-Åkerblom, P ;
Verhagen, W ;
Heim, A .
VIROLOGY, 1999, 265 (02) :178-184
[4]   STUDIES OF IMMUNOGENICITY COMMUNICABILITY AND GENETIC STABILITY OF ORAL POLIOVACCINE ADMINISTERED DURING WINTER [J].
BENYESHM.M ;
MELNICK, JL ;
RAWLS, WE ;
WIMBERLY, I ;
ORO, JB ;
BENPORAT.E ;
RENNICK, V .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1967, 86 (01) :112-&
[5]   Characterization of a recombinant type 3 type 2 poliovirus isolated from a healthy vaccinee and containing a chimeric capsid protein VP1 [J].
Blomqvist, S ;
Bruu, AL ;
Stenvik, M ;
Hovi, T .
JOURNAL OF GENERAL VIROLOGY, 2003, 84 :573-580
[6]   DETERMINANTS OF ATTENUATION AND TEMPERATURE SENSITIVITY IN THE TYPE-1 POLIOVIRUS SABIN VACCINE [J].
BOUCHARD, MJ ;
LAM, DH ;
RACANIELLO, VR .
JOURNAL OF VIROLOGY, 1995, 69 (08) :4972-4978
[7]   Complete genomic Sequencing shows that Polioviruses and members of human enterovirus species C are closely related in the noncapsid coding region [J].
Brown, B ;
Oberste, MS ;
Maher, K ;
Pallansch, MA .
JOURNAL OF VIROLOGY, 2003, 77 (16) :8973-8984
[8]  
CAMMACK N, 1988, VIROLOGY, V167, P507, DOI 10.1016/0042-6822(88)90113-4
[9]  
*CDCP, 2002, MMWR-MORBID MORTAL W, V51, P367
[10]  
Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P913